Real-world data from patients with advanced urothelial carcinoma treated with anti–PD-(L)1 therapy also demonstrated that FGFR3-altered and wild-type tumors have equivalent T-cell receptor diversity, with comparable objective response rates (ORRs), progression-free survival, and OS [24]. Here, FGFR3 is linked to urothelial carcinoma.